

<p>DEPARTMENT OF HEALTH</p> <p>No. 952</p> <p>29 September 2006</p> <p>EXCLUSION OF CERTAIN MEDICINES FROM THE OPERATION OF CERTAIN PROVISIONS OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT NO 101 OF 1965)</p> <p>I, Mandisa Hela, Registrar of Medicines, acting by virtue of a delegation in terms of section 34A of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), hereby exclude in terms of Section 36 of Act 101 of 1965, on the unanimous recommendation of the members present at a meeting of the Medicine Control Council held on 7 July 2006 the medicines listed in the schedule hereto from the operation of the therein listed provisions of the regulations promulgated by Government Notice No. R.510 of 10 April 2003.</p> <p>..... MANDISA HELA REGISTRAR OF MEDICINES</p>	<p>DEPARTEMENT VAN GESONDHEID</p> <p>No. 952</p> <p>29 September 2006</p> <p>UITSLUITING VAN SEKERE MEDISYNE VAN DIE TOEPASSING VAN SEKERE BEPALING VAN DIE WET OP DIE BEHEER VAN MEDISYNE EN VERWANTE STOWWE, 1965 (WET NR. 101 VAN 1965)</p> <p>Ek, Mandisa Hela, Registrateur van Medisyne, handelend kragtens 'n delegasie ingevolge artikel 34A van die Wet op Medisyne en Verwante Stowwe, 1965 (Wet 101 van 1965), en op eenparige aanbeveling van die lede van die Medisynebeheerraad teenwoordig in 'n vergadering gehou op 7 July 2006, sluit hierby uit, kragtens Artikel 36 van Wet 101 van 1965, die medisyne in die Bylae hiervan vermeld van die toepassing van die daarinvermelde bepaling van die regulasies afgekondig by Goewermentskenningsgewing No. R.510 van 10 April 2003, onderworpe aan die voorwaardes ingelys in the Bylae vermeld.</p> <p>..... MANDISA HELA REGISTRATFUIR VAN MEDISYNE</p>
--	--

REGISTRATION NO/ REGISTRASIE NO	NAME OF MEDICINE/ NAAM VAN MEDISYNE	FORM OF PREPARA- TION/ BEREIDINGS- VORM	PROVISIONS FROM WHICH EXCLUDED/ BEPALINGS WAARVAN UITGESLUIT	CONDITIONS OF EXCLUSION/ VOORWAAR-DES VIR UITSLUITING	APPLICANT/ APPLIKANT
A380629	Inflamimide 400 Novolizer		Regulation 8(1): Bilingualism (a) Scheduling status (c) Registration number		Boehringer Ingelheim
21130.11031	OPV-Merieux		Regulation 8(1): Bilingualism (a) Scheduling status (b) Proprietary Name (c) Registration number (p) Name of the Holder of Certificate of Registration Regulation 9(1) Bilingualism	Provided that: - the authorization only be applicable to 7 million doses of trivalent oral polio vaccine intended for a mass polio campaign vaccination in September/ October 2006. - Only supply to the State	Aventis